Indraprastha Medical Corporation Intrinsic Value
Indraprastha Medical Corporation (INDRAMEDCO) median intrinsic value is ₹174.13 from 9 valuation models (range ₹80–₹327), vs current price ₹364.60 — -52.2% downside (Trading Above Calculated Value), margin of safety -100.0%. Read Indraprastha Medical Corporati dividend policy for the complete payout history and dividend yield track record.
INDRAMEDCO Valuation Methods Summary — DCF, Graham Number & P/E
Indraprastha Medical Corporation intrinsic value across 9 models vs current price ₹364.60 — upside/downside and value range per method. For current market price and key ratios, visit Indraprastha Medical Corporati share price today.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹240.36 | ₹192.29 - ₹288.43 | -34.1% | EPS: ₹20.03, Sector P/E: 12x |
| Book Value Method | asset | ₹80.43 | ₹72.39 - ₹88.47 | -77.9% | Book Value/Share: ₹80.43, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹128.96 | ₹116.06 - ₹141.86 | -64.6% | Revenue/Share: ₹161.20, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹174.13 | ₹156.72 - ₹191.54 | -52.2% | EBITDA: ₹267.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹231.80 | ₹185.44 - ₹278.16 | -36.4% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹320.48 | ₹288.43 - ₹352.53 | -12.1% | EPS Growth: 20.0%, Fair P/E: 16.0x |
| Growth Adjusted P/E | growth | ₹171.12 | ₹154.01 - ₹188.23 | -53.1% | Revenue Growth: 13.6%, Adj P/E: 8.5x |
| ROE Based Valuation | profitability | ₹326.96 | ₹294.26 - ₹359.66 | -10.3% | ROE: 25.4%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹160.87 | ₹144.78 - ₹176.96 | -55.9% | EPS: ₹20.03, BVPS: ₹80.43 |
INDRAMEDCO Intrinsic Value vs Market Price — All Valuation Models
Indraprastha Medical Corporation fair value range ₹80–₹327 vs current market price ₹364.60 across 9 valuation models. Analyse INDRAMEDCO shareholder distribution to track promoter, FII and institutional holdings.
INDRAMEDCO Intrinsic Value Analysis — Undervalued or Overvalued?
Indraprastha Medical Corporation median intrinsic value ₹174.13, current price ₹364.60 — Trading Above Calculated Value by 52.2%, margin of safety -100.0%.
What is the intrinsic value of INDRAMEDCO?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Indraprastha Medical Corporation (INDRAMEDCO) is ₹174.13 (median value). With the current market price of ₹364.60, this represents a -52.2% variance from our estimated fair value.
The valuation range spans from ₹80.43 to ₹326.96, indicating ₹80.43 - ₹326.96.
Is INDRAMEDCO undervalued or overvalued?
Based on our multi-method analysis, Indraprastha Medical Corporation (INDRAMEDCO) appears to be trading above calculated value by approximately 52.2%.
INDRAMEDCO Financial Health — Key Ratios vs Industry Benchmarks
Indraprastha Medical Corporation financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 5.15 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 25.4% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 18.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.50x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
INDRAMEDCO Cash Flow Quality — Operating & Free Cash Flow
Indraprastha Medical Corporation operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹157 Cr | ₹102 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹200 Cr | ₹121 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹145 Cr | ₹91 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹94 Cr | ₹57 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹27 Cr | ₹18 Cr | Positive Free Cash Flow | 8/10 |